Article

Repositioning of FDA-approved anti-cancer drugs for fatal blast crisis CML by integrated high-throughput genomic and artificial intelligence-based drug discovery analyses of pan-leukemic genetic abnormalities: Implications in post-COVID-19 era

2025-02-27

Abstract excerpt

<title>Abstract</title> <p><bold>Background:</bold> Chronic Myeloid Leukemia (CML) is a type of cancer that affects the blood and bone marrow. Although treatable in initial chronic phase (CP-CML) and accelerated phase (AP-CML), in its advanced stage, known as the blast crisis phase (BC-CML), it becomes very aggressive and challenging to treat, with overall survival (OS) ranging from few months to less than 2 year...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d092ffc8-4517-55f9-a828-8ec5a97f3579
DOI: 10.21203/rs.3.rs-6071747/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Repositioning of FDA-approved anti-cancer drugs for fatal blast crisis CML by integrated high-throughput genomic and artificial intelligence-based drug discovery analyses of pan-leukemic genetic abnormalities: Implications in post-COVID-19 eraDOI 10.21203/rs.3.rs-6071747/v1Read

Investigations on druggable gene mutations related to AML/ALL lineage genes in Advanced Phases of CML: Implications in patient-tailored therapy of blast crisis CML in TKI eraSemantic proximity Read

Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia.Semantic proximity Read

Shared Genetic and Regulatory Mechanisms in Acute Myeloid Leukaemia and Blast Crisis Chronic Myeloid LeukaemiaSemantic proximity Read

Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoringSemantic proximity Read

A Single-Cell Atlas Identifies Pretreatment Features of Primary Imatinib Resistance in Chronic Myeloid LeukemiaSemantic proximity Read

Targeting FLT3-TAZ signaling to suppress drug resistance in blast phase chronic myeloid leukemiaSemantic proximity Read

Analysis of the transcriptome for novel therapeutic targets, and investigation of the role of APOBEC3B in chronic myeloid leukaemia stem cellsSemantic proximity Read

Investigations on Clinical Validation of mutated ANKRD36 as a Novel Molecular Biomarker for Monitoring Early Progression and Timely Therapeutic Interventions in Blast Crisis CMLSemantic proximity Read

Identifying effective drug combinations for patients with acute myeloid leukemia.Semantic proximity Read

Prognostic Factors and Clinical Outcomes in Patients with Blast Phase Chronic Myeloid Leukemia.Semantic proximity Read

Clinical insights into hematologic malignancies and comparative analysis of molecular signatures of acute myeloid leukemia in different ethnicities using an artificial intelligence offering.Semantic proximity Read

Next-generation DNA sequencing identifies mutated FANCD2 Gene as a novel Biomarker for monitoring early disease progression and timely therapeutic interventions in advanced phase Chronic Myeloid Leukemia patientsSemantic proximity Read